• One Health
  • Pain Management
  • Oncology
  • Geriatric & Palliative Medicine
  • Ophthalmology
  • Anatomic Pathology
  • Poultry Medicine
  • Infectious Diseases
  • Dermatology
  • Theriogenology
  • Nutrition
  • Animal Welfare
  • Radiology
  • Internal Medicine
  • Small Ruminant
  • Cardiology
  • Dentistry
  • Feline Medicine
  • Soft Tissue Surgery
  • Urology/Nephrology
  • Avian & Exotic
  • Preventive Medicine
  • Anesthesiology & Pain Management
  • Integrative & Holistic Medicine
  • Food Animals
  • Behavior
  • Zoo Medicine
  • Toxicology
  • Orthopedics
  • Emergency & Critical Care
  • Equine Medicine
  • Pharmacology
  • Pediatrics
  • Respiratory Medicine
  • Shelter Medicine
  • Parasitology
  • Clinical Pathology
  • Virtual Care
  • Rehabilitation
  • Epidemiology
  • Fish Medicine
  • Diabetes
  • Livestock
  • Endocrinology

Aratana Therapeutics receives FDA approval of canine appetite stimulus


Entyce is a first-of-its-kind therapeutic for inappetent dogs.

Images courtesy of Aratana TherapeuticsAratana Therapeutics Inc. has received approval from the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) of Entyce-a first-of-its-kind ghrelin receptor agonist that stimulates appetite in dogs-according to a company release.

Entyce, a new chemical entity, works by mimicking the hunger hormone ghrelin to stimulate appetite. The prescription medication is a flavored liquid that is administered orally.

“Nearly 10 million dogs are diagnosed with inappetence each year and we believe Entyce will fulfill a significant unmet need to stimulate appetite in dogs,” says Steven St. Peter, MD, president and chief executive officer of Aratana Therapeutics, in the release. Aratana is reportedly planning a February 2017 commercial launch of Entyce in order to coincide with the North American Veterinary Conference.


Related Videos
© 2023 MJH Life Sciences

All rights reserved.